Neurocrine Biosciences (NBIX) Misses Q1 EPS by 114c; misses on guidance
Tweet
Share
E-mail
Get Alerts NBIX Hot Sheet
Price: $149.50 --0%
EPS Growth %: -12.4%
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
USAU, IH, CCL, More
EPS Growth %: -12.4%
Financial Fact:
Net income (loss): -36.89M
Today's EPS Names:
USAU, IH, CCL, More
Join SI Premium – FREE
Neurocrine Biosciences (NASDAQ: NBIX) reported Q1 EPS of ($0.51), $1.14 worse than the analyst estimate of $0.63. Revenue for the quarter came in at $410 million versus the consensus estimate of $410.82 million.
GUIDANCE:
Neurocrine Biosciences sees FY2023 revenue of $1.67-1.77 billion, versus the consensus of $1.81 billion.
For earnings history and earnings-related data on Neurocrine Biosciences (NBIX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Lennar Corp. (LEN) Misses Q3 EPS by 10c
- Kestra Medical Technologies, Ltd. (KMTS) Reports Q1 Loss of $0.75/sh
- Amer Sports raises Q3 2026 outlook, updates long-term targets
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
